Abstract: Migraine is a painful, sometimes debilitating disorder, which is frequently associated with various neurological symptoms. Its prevalence in the population is higher than that of any other neurological disorders, thus the burden of this disease on society is considerable. Although the introduction of triptans nearly two decades ago revolutionized the treatment of the disease there is still a huge unmet need regarding drugs with better properties. Formerly, migraine therapy primarily aimed at treating the pathological alterations of meningeal blood vessels that are thought to directly initiate a migraine headache attack. By now, it has been increasingly recognized by drug companies that abnormal neural function may be more important in the development of the disease and also in triggering an attack. Migraine is associated with an increased neuronal excitability and episodes of cortical spreading depression. Understanding the molecular mechanisms underlying the abnormal functioning of over-activated neuronal circuits may help to identify novel anti-migraine drug targets. Besides a general description of the pathophysiology and pharmacotherapy of migraine this review paper aims at discussing the possible drug targets through which migraine-related hyperexcitability and over-excitation can be attenuated. It will be shown how these new ideas appear in the recent patent literature.
INTRODUCTION
Migraine is a common neurological disorder, which is characterized by intense, unilateral, throbbing and pulsatile headache attacks, lasting for 4-72 hours and accompanied by anorexia, nausea, vomiting, photophobia and/or phonophobia [1] . These symptoms distinguish migraine from tension-type and other rare forms of primary headache, which lack these associated features. Because of its high prevalence among population and considerable burden on the society the thearapy of migraine is an issue of high importance. Although the introduction of triptans nearly twenty years ago revolutionized the treatment of the disease there is still a huge unmet need regarding drugs with better properties. Recent patent applications indicate that several drug companies are very active in research for identifying new anti-migraine agents. Their efforts are helped by a considerable progress in understanding of migraine pathogenesis made in the last 2 decades (see for example [2, 3] for reviews), However, the pathomechanism underlying this complex disorder still has not been completely understood.
Until recently, migraine was mainly regarded as a disease of blood vessels [4] , and neurological symptoms were thought to be the result of vascular problems. Now, it is widely accepted that it is some pathological changes occurring in the nervous system that triggers migraine attacks, and dilation of meningeal arteries is a consequence rather than a triggering event. Abnormal neuronal activity is accompanied with not only the attacks themselves, but also with the so-called interictal phases of the disease [5, 6] . Furthermore, advanced imaging techniques revealed episodes of cortical spreading depression (SD) in the aura phase in patients with migraine with aura [7, 8] , and enhanced neuronal/cortical excitability was demonstrated also in the periods between attacks [9] . Although there are conflicting opinions among researchers regarding the role of cortical hyperexcitability in the pathomechanism of migraine and it is also disputed whether SD is a trigger for attacks, or just a neurophysiological correlate of aura phenomena [5, 9] . Nevertheless, the majority of experimental findings support the view that cortical cells are hyperexcitable in migraine.
Recognition of the occurrence of cortical SDs concomitant with aura phenomena, and their implication in triggering the headache can be regarded a breakthrough in identifying novel targets in anti-migraine drug research. It has become evident that migraine shares several similarities to other central nervous system diseases [10] . Stroke is also accompanied by an over-excited state of neurons in the area of penumbra, where repetitive occurrence of SDs clearly contributes to the pathology [8, 11, 12] . Enhanced activity of neurons in particular regions of the central nervous system is also a characteristic feature of a wide group of other central nervous system diseases. Such disorders, the so-called neuronal hyperexcitability disorders include among others epilepsies, chronic neurodegenerative diseases, chronic pain states and several psychiatric conditions [6, 13] . Using the working hypothesis that migraine also belongs to the group of hyperexcitability disorders it is reasonable to investigate if the knowledge collected from the pharmacotherapy of these diseases may be applicable also to the migraine field. In fact, several antiepileptic agents are used in the therapy of migraine too [14, 15] . Several novel drug targets have emerged during the last decades, through which abnormal neuronal excitability can be decreased, and it is logical to suppose that these can be useful also as anti-migraine drug targets. It is believed that therapeutic approaches targeting neural rather than vascular mechanisms offer better control of attacks and could interfere with the development and perpetuation of the disease [16, 17] . Sensitization of perivascular nerve endings and that of multiple elements of pain pathways involved in headache are characteristic features of migraine pathophysiology. Neuronal hyperexcitability definitely plays a role in both peripheral and central sensitization. These characteristics are shared with other chronic pain states, where reduction of excitation is a widely used therapeutic approach.
Besides a general description of the pathophysiology and pharmacotherapy of migraine we are going to focus our review on established and potential new targets of neuronally acting anti-migraine agents, and to show how these new ideas appear in the recent patent literature.
DESCRIPTION OF THE DISEASE
Migraine is a chronic neurological disorder with episodic manifestations that can be triggered by several factors, such as stress, hormonal changes, foods, weather or odors, etc. It is characterized by recurrent attacks of nervous system dysfunction and headache with a return to baseline between attacks [18] . Criteria specified for migraine by the International Headache Society [1] are the followings:
-repeated attacks of headache lasting 4-72 hours with normal physical examination and no other cause for the headache.
-at least two of the following symptoms: unilateral pain, throbbing pain, moderate or severe intensity, aggravation on movement.
-at least one of the following symptoms: nausea or vomiting, photophobia and phonophobia.
These symptoms and some associated features described below distinguish migraine from tension-type and other forms of primary chronic headache disorders. Responsiveness to anti-migraine therapy also helps classification [19, 20] .
In about 20% of patients, an aura may precede the migraine headache (classical migraine; migraine with aura; MA). The typical aura of migraine is characterized by focal neurological features that usually precede a migraine attack by about 1 hr. The rest of migraineurs do not sense aura symptoms (common migraine, migraine without aura; MO). Auras are most frequently visual, such as scintillating scotomas, stars, or tunnel vision but can involve other senses (feeling strange odors, tingling or numbness of extremities) as well. Occasionally motor or speech deficits are reported [21] .
The usual course of a typical migraine attack contains at least four phases, however these do not necessarily occur, and there is no distinct onset or end of each stage. The migraine cycle starts with the prodromal phase, which is experienced by most patients with the clinical signs of sensory hyperexcitability, such as photo-and phonophobia, and cutaneous allodynia on the face. This phase may be associated with malaise, fatigue, changes in mood and appetite, and precedes the headache attack by several hours, sometimes a day. Auras sometimes occur just before or simultaneously with the headache, typically developing gradually over 5 to 20 minutes and lasting for less than 60 minutes. The headache phase is the most disabling stage of the attack that generally lasts for 4-72 hours. Headache is usually unilateral, pulsatile and is exaggerated by coughing or physical activity. In many cases, pain is accompanied by nausea and a severe sensitivity to environmental stimuli. The headache phase usually fades from the maximum intensity over the lapse of the hours. The relief phase of the attack is followed by a postdromal phase, in which patients commonly complain about tiredness and describe obvious markers of neural hyperexcitability, such as photophobia and allodynia [22] . Periods between attacks are referred to as interictal phases.
In milder forms of the disease migraine attacks occur with a frequency of one, or less than one attack per month, but frequently appears as a chronic daily headache. Chronification of the disease, i.e. progressive increase of attack-frequency accompanied by structural and physiological changes in the affected (pain processing) brain areas can sometimes be observed clearly [23] . Due to hormonal and other, less understood changes the occurrence of the attacks decreases after 50 year of age. In the Western Countries, the one-year prevalence of migraine is 11% overall: 6% among men and 15-18% among women. The prevalence of migraine is 2-3 fold higher in women than in men [24] [25] [26] and migraine attacks in women are influenced by the menstrual cycle, suggesting that fluctuation of the level of female sexual steroids probably play a role in the pathomechanism [3, [27] [28] [29] . Although attacks of migraine may start at any age, they typically appear in early to midadolescence. Migraine prevalence peaks between the ages of 35-45 years [24] , a period which is most productive in life. Thus, not only does migraine reduce quality of life, as evidenced by the fact that the WHO ranks it among the world's most disabling illnesses (WHO, 2001), but it also results in a considerable economic loss to the society in terms of lost workdays [30] .
MIGRAINE PATHOMECHANISMS

Genetics
Migraine has a strong (up to 50%) genetic component, which is higher in MA than MO, with a probable multifactorial polygenic inheritance [31] . The genes involved in the pathophysiology of migraine are difficult to search as migraine is an episodic disorder displaying both a clinical and a genetic heterogeneity. However, three migraine-related genes have now been identified in families with various forms of familial hemiplegic migraine (FHM1-3), all displaying an autosomal dominant inheritance pattern. These genes include Ca V 2.1 (P/Q-type) Ca 2+ channel 1-subunit gene in FHM1 [32] , Na + /K + -ATPase 2-subunit gene in FHM2 [33] and a neuronal voltage-gated sodium channel (VGSC) gene in FHM3 [34, 35] , which are all involved in transmembrane ion transport. Possibly, these genes could also have a role in more common forms of migraine [36] . It is not exactly known how these mutations could trigger migraine attacks, but it is believed that alterations in intracellular calcium concentrations and abnormal potassium levels, leading to increased neuronal excitability, play a critical role.
Triggering and Maintaining Migraine Headache
Although the pathophysiology of migraine is largely unknown, migraine attacks most probably start in the brain, possibly within the brainstem [37, 38] . Early recognition that attacks of migraine headache are accompanied with changes in brain blood vessels led to the vascular theory of migraine [8, 28] . The basic assumption of this theory is that vasodilation of meningeal blood vessels is the immediate cause of headache. The theory is supported by the observation that most clinically effective anti-migraine agents constrict blood vessels in various in vitro and in vivo models, and also in patients. Recently, however, a huge body of experimental evidence, indicating the importance of neuronal changes in the pathomechanism of migraine, challenges the vascular theory.
Migraine is better understood as a neurovascular disorder; where neuronal events likely underlie the dilation of blood vessels, which in turn induces pain and further nerve activation [8, 18] . The basic mechanisms believed to be involved in migraine pathophysiology are: (i) neuronal hyperexcitability during the interictal phase [39] [40] [41] associated with an altered function of pain controlling structures in the midbrain; (ii) cortical SDs during the aura phase, or just preceding the headache phase in the case of MO; and (iii) activation and sensitization of the trigeminovascular system at peripheral and central levels that result in cranial vasodilation. This trigeminal stimulation may involve the release of nitric oxide (NO) [42] and certain neuropeptides, particularly calcitonin gene-related peptide (CGRP) [2, 43] ; thus reinforcing vasodilation and perivascular nerve activity [3] , and inducing inflammation of the perivascular tissue, and sensitization of afferent terminals (peripheral sensitization). While the early events during a migraine attack are unlikely to account for the headache, because the brain is largely pain-insensitive, trigeminal activation and vasodilation together are most probably responsible for the headache phase [44] . It is supposed that dilation and pulsation of meningeal vessels activate sensitized terminals of afferent trigeminal fibres, and an intense and persistent barrage of the nociceptive impulses induces amplification of pain signals due to plastic changes in brain structures involved in processing and transmitting these signals to higher centres. This so-called central sensitization is a common feature of several chronic pain states, and is accompanied with enhanced excitatory neurotransmission and increased excitability of neuronal structures Fig. (1) .
Current evidence indicates that cortical spreading depression (CSD) is the most probable primary event in trigeminovascular system (TGVS) activation in migraine with aura and, perhaps, also migraine without aura. Dysfunctional brainstem nuclei involved in the central control of pain might exert a permissive role by favouring central trigeminal hyperexcitability. Abnormal cortical activity might lead to CSD when enhanced activation coincides with other triggering factors. The relationship between abnormal cortical activity and abnormal brainstem function is unclear (adopted with modifications from Pietrobon and Striessing [12] .
Abnormal cortical and brainstem activity as well as sensitization of the trigeminovascular system are involved in the precipitation of migraine attacks. Recurrent migraine attacks may lead to subsequent change in phenotypic expression of the disorder, as well as the chronification of the disease in several cases [23] .
Cortical Spreading Depression (SD)
Aura and headache are temporally linked manifestations of migraine. It was proposed long time ago that the migrating cortical inactivation known as cortical SD is likely responsible for the marching sensory deficit often dominating migraine aura [8, 45, 46] . Moreover, migraine aura is probably under-reported by patients because when association cortex is affected, there may be no perceived deficit. It is therefore possible that processes underlying aura activate the pathways responsible for the subsequent migraine pain.
The phenomenon of SD was discovered by A. Leao in 1944 [47] , and described as a profound but transient depolarization of neurons and glia that migrates across the cortical and subcortical gray matters at 2-5 mm/min and is followed by long-lasting suppression of neuronal activity. Cortical SD is accompanied with disturbed ion homeostasis, excessive release of neurotransmitters and a negative shift of the field potential. Cortical SD is initiated by local overexcitation of neurons characterized by high and synchronized firing activity, underlying elevation of potassium concentration in the extracellular space, as well as increased glutamate release from terminals of excitatory neurons, which result in further excitation of adjacent cortical areas. Increased neuronal activity is followed by long-lasting suppression due to a depolarization blockade [46] . Cortical SD can be induced experimentally in normal cortical tissue; in brain slices as well as in the brain of intact animals, when excitatory substances such as high concentration of potassium, or glutamate receptor agonists are applied locally [48, 49] . Astroglial cells, which play a principal role in the regulation of extracellular glutamate concentration and in the maintenance of normal ionic milieu [50] are thought to be intimately involved in the generation and propagation of cortical SD waves [51] . Glutamate released from astrocytes through volume-sensitive organic anion channels, as well as communication between glial cells via gap junctions and the so-called glial calcium waves may be important regarding these processes [52] . Occurrence of SD-like events in the brain of migraine patients has been confirmed by noninvasive imaging methods, and by electrophysiology [7, 37, 38] . This physiological event seems to trigger migraine aura. Cortical SD causes the dilation of cortical meningeal vessels, resulting in a short-lasting increase in regional cerebral blood flow (CBF) i.e. hyperperfusion, which is followed by a longlasting hypoperfusion. Transient extracellular pH changes (acidosis) and accompanying cation shifts (especially outward potassium flow) contribute to the dilation of meningeal blood vessels and activation of trigeminal afferents during spreading depression events. Most presently used migraine therapies try to treat the disease at the vascular site, thus temporally downstream from aura generation. However, the intimate relationship between cortical neuronal excitability and cortical SD with the initiation of migraine attacks suggest that factors that determine excitability can be regarded as potential anti-migraine drug targets.
NEURONAL EXCITABILITY AND ITS CHANGES IN PATHOLOGICAL STATES
Factors playing a critical role in setting neuronal excitability include several voltage and ligand-gated ion channels responsible for maintaining the resting membrane potential, and transport proteins, such as the Na + /K + exchanger. Pump mechanisms require ATP thus maintenance of ion homeostasis depends on cell energy supply. Mainly sodium channels determine firing characteristics of neurons, but several factors, such as G-protein coupled receptors participate in the complex regulation of these channels via activating a great variety of intracellular signaling cascades and a subsequent phosphorylation of the channel protein mediated by protein kinases [53, 54] . Release of both inhibitory and excitatory transmitters is also under the regulation of voltage gated channels. Certain types of calcium channels play a major role in triggering vesicular processes, but VGSCs are also important by conveying presynaptic action potentials to near the axon terminals, thus depolarizing the presynaptic membrane so that voltage gated calcium channels (VGCC) can open.
In certain neurological and psychiatric diseases, excitatory processes overwhelm inhibition, and normal brain functioning is disturbed by an increased background noise in neuronal activity. Milder forms of increased excitability, which are limited to circumscribed brain regions, occur in some psychiatric disorders, such as anxiety or obsessivecompulsive disorder. Even more excitation leads to more serious symptoms, such as epileptic seizures, and extreme over-excitation can lead to neural and glial cell death, called excitotoxicity [55] , as occurs following severe brain ischemia. Drugs that decrease excitatory tone may be beneficial in all these states [13] .
CURRENT THERAPY
Before discussing pharmacotherapy, it is interesting to mention some novel non-pharmaceutical treatments that may gain an important role in the treatment of migraine patients, although these procedures are in experimental phase, and the usefulness of some of them is not accepted unanimously. These include occipital-and vagal nerve stimulation via implanted devices [56] [57] [58] [59] . Cortical excitability can be altered by trans-cranial magnetic stimulation, and several claims for simple, patients-operated devices working on this principle have appeared in the patent literature [60] . It may be interesting to mention here that trans-cranial DC stimulation is also a possible way to influence cortical excitability [9] . The possible beneficial effect of surgical closure of patent foramen ovale was investigated in a controlled trial, but no significant improvement in the patient's state has been reported [61] .
Drugs for the treatment of migraine (listed in Tables 1-3) can be divided into preventive and acute (abortive) antimigraine drugs [18] , although a clear distinction is sometimes difficult to make, since the same drug may be used for both purposes. Prophylactic agents are prescribed only when frequent occurrence of attacks justifies it (exceeds two attacks or more per month), and are usually taken for at least three months whether or not the headache is present. They   Fig. (2) . Some important compounds used for the prevention of migraine attacks. Flunarizine HCl (1), topiramate (2), amitriptyline HCl (3), timolol maleate (4) and valproate semisodium (5) .
.HCl are expected to reduce the frequency, duration and severity of attacks, while acute drugs are taken to treat attacks when they arise. In the USA, only four drugs have been approved by the FDA for prevention of migraine, propranolol and timolol ( adrenoceptor blockers) and divalproex sodium and topiramate (anti-seizure drugs), but several other agents have been acknowledged as anti-migraine drug in other countries, and even more are used off-label for the treatment of migraine. The most popular prophylactic treatments for migraine include calcium channel blockers [62] , especially flunarizine, 5-HT 2 receptor antagonists, -adrenoceptor blockers, monoamine uptake inhibitors, and antiepileptic agents with various mechanisms of action, first of all VGSC blockers [63] ; see Table 1 for further agents). Unfortunately, most of these drugs offer non-specific treatment, i.e. they are not optimized for anti-migraine activity, and are not always effective in all patients. Methysergide was the first agent specifically developed for the prophylactic treatment of migraine, but it is not recommended any more.
Acute treatment of migraine attacks can be further divided into non-specific and migraine specific treatments. Non-specific treatments of migraine headache, such as aspirin and other over-the-counter non-steroidal antiinflammatory drugs, opiates and combination analgesics are used to treat a wide range of other types of pain disorder. A new formulation of diclofenac potassium (PRO-513), which utilizes a unique, Dynamic Buffering Technology to improve the pharmacokinetic profile of diclofenac was recently introduced for the treatment of migraine attacks. Besides headache, this preparation seems to be able to treat photoand phonophobia and nausea associated with migraine Further ergot compounds, such as dihydroergotamine, mesulergide, metergoline and lisuride are also traditionally used in migraine therapy. Some are also useful as prophylactic agent.
Fig. (3).
Chemical structures of triptan compounds. Sumatriptan (6), almotriptan (7), eletriptan (8) , naratriptan (9), zolmitriptan (10), frovatriptan (11) and rizatriptan (12) . (11) attacks. A common risk with the drugs belonging to this category is the possible development of rebound headache associated with "medication overuse" [64] thus, frequency of their use should continue to be limited. It is to be noted, however, that this type of rebound phenomenon is also observed with specific anti-migraine therapies, such as ergot compounds or triptans. Dopamine D 2 receptor antagonists represent another group of anti-migraine compounds, which are mainly used to attenuate vegetative symptoms (nausea and/or vomiting) associated with migraine attacks.
The mainstay specific acute anti-migraine therapy for patients with moderate-to-severe migraines has been the triptan class since theirs launch in the early 1990's. The triptans are serotonin 5-HT 1B/1D receptor agonists that target sensory nerves and constrict dilated intracranial blood vessels, thus decreasing inflammation, and restoring corrupted blood supply by closing arteriovenosus anastamoses. Neuronal actions of triptans, such as inhibition of the release of vasoactive neuropeptides (most importantly CGRP) from both peripheral and central sensory nerve endings also significantly contribute to their pharmacological effects [65] . At the present stage seven triptans ( Table 3 ) are in commercial use, which differ from each other in efficacy, pharmacokinetics, tolerability, etc. Eletriptan is the most effective, but also has severe side effects. Naratriptan and frovatriptan have fewer side effects and a lower rate of recurring headache. Sumatriptan, the gold standard of migraine therapy, is used not only in oral formulation, but also as subcutaneous, suppository and nasal spray formulations.
Before the triptan era, ergot derivatives, introduced in the 1950's, used to be the first-choice acute therapy for migraine. Their mechanism of action is based on their serotonin agonist effect. Of the first ergoline derivative drugs, dihydroergotamine is a relatively pure 5-HT 1D agonist; while -dihydroergocryptine also has -adrenoceptor antagonist activity. Some derivatives, e.g. ergotamine tartrate, lisuride and metergoline, also possess dopamine D 2 agonist potency.
Synergistic drug interactions may enhance therapeutic actions. Metoclopramide, by increasing intestine motility, helps and accelerates the absorption of simultaneously, or subsequently taken ergot derivative, and can also prevent migraine attack-associated nausea. Combinations of drugs with different modes of action, such as ergots, cyclooxygenase (COX) inhibitors, caffeine or barbiturate derivatives have been traditionally used in the treatment of migraine; the different combinations are thought to potentiate each-other's effects. The experience with combination therapy was reviewed recently by Krymchantowski and Jevoux [66] . The latest development in this field is that early this year GalxoSmithKline and Pozen received FDA approval of Treximet, a combination of sumatriptan and naproxen, for the treatment of migraine attacks both with or without aura. A metoclopramide plus naproxen combination was also introduced recently by Pozen.
Preparations of herbal medicines, such as feverfew, butterbur or goshuyuto, possessing anti-inflammatory effect are also available for the preventive treatment of migraine [67] .
SIDE EFFECTS OF CURRENTLY USED DRUGS, UNMET NEED
The most popular drugs against migraine are the triptans. Novel triptans have more advantageous side-effect profile than that of the prototype compound sumatriptan, but some can still cause serious cardiovascular problems like stroke, myocardial infarction, uncontrolled arterial hypertension, or Raynaud's syndrome. Thus, triptan treatment is contraindicated in patients with vascular diseases. Furthermore, these drugs affect serotonin levels, and they may cause serotonin syndrome via drug interactions with antidepressants. Pain in the chest, muscle weakness, tachycardia, tingling and numbness in the toes, nausea, drowsiness or dizziness are sometimes also associated with triptan treatment [68] . Ergots have rather similar side effect profile [69] . Although triptans are safe and effective, they provide the relief of headache at 2 hours post dose only in between 50-70% of patients and only up to 60% of patients become pain-free within this period [70, 71] . Moreover, frequently only temporary relief is achieved and headache returns after a few hours. Thus agents having faster-onset and longer-lasting action are badly needed.
Many agents used in migraine prophylaxis that act via decreasing neuronal excitability, such as GABAergic drugs, sodium channel blockers, glutamate antagonist and calcium channel blockers, may have central nervous system Fig. (4) . Chemical structures of some ergot compounds used in the therapy of migraine. Ergotamine (13a), dihydroergotamine (13b), metergoline (14) and lisuride (15) . depressing side effects. These include ataxia, dizziness, drowsiness, fatigue, headaches, and visual disturbances. Others may cause weight gain or loss, ringing in the ear, or agitation. Very frequent non-CNS side effects are cardiovascular and gastrointestinal problems, which are also typically associated with the use of nonsteroidal antiinflammatory drugs. COX-2 selective inhibitors are favorable regarding the gastrointestinal tract, but they are not free from the cardiac effects of COX inhibitors, which seriously restricts their use. Antidepressants are effective in preventing migraine, likely due to their effects on the serotonergic system. Tricyclics are the most successful ones, probably because of their additional VGSC blocking efficacy. However, they can have side effects, most importantly weight gain and dry mouth, and disturbances in the heart rhythm in overdose. Opiates, which are not really effective in migraine, also have well-known side effects including sedation, nausea, constipation, or impaired judgment, and the risk for addiction, thus their use should be avoided. Beta-blockers should not be taken by patients with asthma or certain heart conditions. Side effects like fatigue, lethargy, depression, nightmares, memory loss, dizziness, impaired heart function, and sexual dysfunction may occur.
During the last decades, acute treatment of migraine has been dominated by serotonin modulators (triptans and ergotamine derivates) primarily acting on blood vessels, but increasing recognition of migraine as a neuronal rather than a vascular disorder highlights the need for drugs that target the triggering processes underlying the attack, rather than the consequences of these changes. Neurophysiological and functional imaging studies of the last few years clearly suggest that hyperexcitability of the trigeminal system as well as central sensitization of brainstem sensory nuclei are playing key roles in migraine's pathomechanism [72, 73] . Furthermore, the cortex is hyperexcitable in migraineurs; cortical SD, which is thought to underlie the aura phenomena and likely to act as a trigger of a migraine attack is a clear sign of neuronal hyperexcitability [6, 40, 41, 74, 75] . The central role of enhanced excitability in the pathomechanism of migraine suggests that all those therapies successfully applied in the treatment of neuronal hyperexcitability disorders, such as chronic pain, muscle spasticity, epilepsy, etc., may be suitable for the treatment of migraine as well. However, not all of these therapeutical strategies have been tested systematically for migraine indication. It is logical to suppose that drugs interfering with the neuronal processes underlying cortical SD should be suitable to stop an attack as well. Indeed, several anti-migraine agents have been found to stop SD in in vitro and in vivo models [76] . Paradoxically, these drugs, when applied acutely are not able to abort an ongoing migraine attack in patients. Rather, efficaciousness in SD/migraine models can be taken as an indication that the drug will be suitable as a preventive treatment when applied chronically. What an SD inhibitory action in these models indicates is that the drug is able to lower excitability. Sustained suppression of excitation may lead to a weakened central sensitization and may lower predisposition to cortical SD, the key mechanisms in triggering migraine headache. In theory, drugs that are able to stop an ongoing SD, applied when the first aura signs appear, would be ideal for acute treatment.
AGENTS UNDER PRE-CLINICAL AND CLINICAL DEVELOPMENT
According to the Integrity compound database (Prous Science, S.A., Barcelona, Spain) more than 60 agents are under active development for the treatment of migraine. About half of them are known drugs being developed for migraine as a new indication, or new formulations of known anti-migraine agents. The rest include new chemical structures, many acting on established anti-migraine drug targets, while some acting on proteins have only been recently implicated in the pathomechanism of migraine. In some cases no information about the mechanism of action is available. The limitations of this review only allow the discussion of some interesting trends of anti-migraine drug research. New compounds under active clinical development are listed in Table 4 , while the most interesting compounds tested in the pre-clinical phase will appear in the section about potential drug targets. A few important drug candidates, close to the launch to the market, are introduced below.
As an example for drugs already in use for non-migraine indications, but being developed against migraine botulinum neurotoxin type-A (BoNT/A) can be mentioned. It is a toxin derived from the anaerobic microorganism Clostridium botulinum, and further to its use as a cosmetic treatment, it is also used in the therapy of painful muscle spasms. Allergan's product, Botox, is in active development for migraine prophylaxis. Some of the results are rather disappointing [77] , however, the latest trial in chronic migraine patients is clearly positive [78] . To prevent headache BoNT/A has to be injected intramuscularly to cranial muscles. Lacosamide (Vimpat), recently introduced for the treatment of diabetic neuropathic pain, and partial epilepsy, is also tested by UCB in migraine patients (Phase II), as a prophylactic agent. Loxapine, which is used in the therapy of mood disorders, as well as several COX inhibitor analgesic and drugs and agents used in the therapy of hypertension are also being investigated for efficacy against migraine.
GSK's sumatriptan, the prototype triptan compound, is also available in parenteral formulations in the USA. New formulations are being developed with other triptans too.
Among anti-migraine compounds under active preclinical and clinical development there are several CGRP receptor antagonists. Proximagen and Noxxon are developing their compounds, PRX-2, and NOX C-89, respectively, in preclinical phase. BMS-694153 of displayed rapid and efficient intranasal exposure in animal experiments [79] . MK-3207 and MK-0974 are investigated in Phase II and Phase III, respectively, in patients with acute migraine [80] . CGRP antagonists are regarded as drugs that may revolutionize migraine therapy.
MOLECULAR TARGETS OF ANTI-MIGRAINE DRUGS
In this part, we overview the already established molecular targets of anti-migraine drugs. Some membrane proteins that are implicated in the regulation of central nervous system excitability will also be discussed, since their modulation offers theoretical possibilities to intervene in the disease process. This review focuses on drug targets through which pathologically increased neuronal excitability associated with migraine can be decreased. However, a clear distinction between neuronal and vascular mechanisms is sometimes not easy to make. Compounds that exert a therapeutic action on blood vessels may also affect neuronal functions. Triptans, for example, cause vasoconstriction via vascular 1B-type serotonin receptors, but also modulate the release of substances from afferent nerve terminals via 1D and 1F type receptors [65, 81] . Moreover, the same receptors can be expressed on both neural and vascular elements, and the same receptor-mediated or ion conductance mechanisms may be important in both vascular and neuronal functions. Another aspect of the complex relationship between the vascular and neuronal systems is that impairment of cerebrovascular functions results in brain ischemia, which has great impact on neuronal functions and can increase neuronal excitability [82] . In fact, brain hypoxia has been implicated in the pathomechanism of migraine [83, 84] , and there are similarities between the mechanisms underlying ischemic stroke and migraine [13] .
CGRP RECEPTORS
A good example of mechanisms involved in both vascular and neuronal changes in migraine is related to CGRP receptors. CGRP is released from both peripheral and central primary afferent terminals, which contributes to vasodilation of arteries, generation and maintenance of neurogenic inflammation associated with migraine as well as other pain states, but also in the control of neuronal excitability [85] . Storer and coworkers demonstrated that CGRP receptor antagonists applied iontophoretically onto neurons of the trigeminocervical complex of anesthetized cats decreased responses evoked by stimulation of the superior sagittal sinus [86] . The CGRP receptor is thought to be an ideal anti-migraine drug target through which the disease process can be attenuated selectively, with low sideeffect risk. Several drug companies are engaged in research for antagonists of this receptor (see later).
5-HT RECEPTORS
The family of 5-HT receptors probably represents the most widely studied class of anti-migraine drug targets. Compounds preferentially acting on 1D and 1F type receptors are regarded preferable over 1B ligands, since they are supposed to have lower risk of cardiovascular side effects. Thus several 1F activators with structures unrelated/ independent from that of triptans are being developed [65] . Antagonists of 5-HT 2 receptors are also well-established anti-migraine drugs. Increasing mass of data supports the concept that activation of 5-HT 7 receptors is a major factor responsible for the initial dilation of cerebral vessels and the subsequent activation of sensory pathways, consequent to neurogenic inflammation around the meningeal vessels, neural sensitization and activation of hyperalgesic pain [21] . Further to their roles in vascular events, 5-HT 7 receptors, just like 5-HT 2 receptors, may contribute to neuronal overexcitation during a migraine attack. It is not clear, however, to what extent neuronal effects of 5-HT receptor ligands are responsible for their anti-migraine effects.
ADRENERGIC RECEPTORS AND NO
Adrenergic receptors are also important regulators of excitability and some blockers, applied chronically, have an important role in migraine prophylaxis.
NO participates in both vasodilation and in altered neuronal functions during migraine. NO increases neuronal excitability by inhibiting resting potassium conductances via the cGMP/PKG pathway [87] . Several drug companies are active in neuronal NO synthase inhibitor research, Proximagen develops its compound, PRX-2, in migraine direction. Proteins involved in NO-associated signal transduction cascades are also potential targets of anti-excitatory pharmacotherapy.
COX INHIBITORS
COX inhibitors are regarded as non-specific treatment of migraine headache, but COX may also be involved in the regulation of cortical excitability. Naproxen, applied intravenously, has been shown recently to inhibit the sensitization of trigeminovascular neurons [88] and that of peripheral nociceptors [89] , suggesting a critical involvement of arachidonic acid metabolism in both central and peripheral sensitization associated with migraine. Older tools of central nervous system-preferring analgesic agents, such as acetaminophen or paracetamol, still have a significant role in the therapy of migraine headache. Opiates are sometimes also applied in drug-resistant cases, but their use is seriously limited by side effects. Nasal (butorphanol) and oral transmucosal (fentanyl) application of opiates decrease sideeffect risks.
VGSCs
VGSCs have vital physiological functions but also play important roles in several pathological processes of the nervous system. Epilepsy, neurodegenerative disorders, muscle spasticity disorders and either neuropathic or inflammatory pain syndromes commonly called hyperexcitability disorders are all characterized by an over-excited state of specific groups of neurons, and by an abnormally increased activity of sodium channels (see [90] for review). Blocking the function of VGSCs alleviates the symptoms of these diseases and counteract disease progression. VGSC inhibitors are useful for the treatment of epilepsy, chronic pain and bipolar disorder [91] . According to the recently published hypothesis of Cohen [92] most of the commonly used drugs for migraine prophylaxis may act at least partly through the inhibition of sodium channels. Evidence exists that the well-known VGSC blocker lamotrigine is effective in preventing migraine headache [93] and the aura of migraine [94] , although negative clinical results have also been published [95] . Blockade of VGSCs can block SD in vitro [96] , and in vivo as well [97] . Although the involvement of VGSCs in many vital physiological functions would suggest a high side-effect risk of drugs acting on this target, some of the new VGSC blocking drug candidates, such as the phenylpiperidine-carboxamide derivative PPPA [98] , possess a highly state-dependent blocking action on VGSCs, which can guarantee a low side-effect profile at therapeutic doses. There are several recently filed patents, and promising developmental drug candidates among VGSC blockers aimed at treatment of hyperecitability related disorders, including migraine [90, 99] . The main functions of VGSCs are generation and propagation of action potentials, however, some subtypes (Na V 1.3, Na V 1.7) can also produce noninactivating currents at a certain membrane potential range, therefore have a considerable role in the regulation of membrane excitability. Small leak sodium currents produced by the non-selective sodium leak channels (NALCN), a recently described family of non-voltage dependent sodium channels [100] , may have a major role in setting the membrane potential of neurons.
VGCCs
The use of verapamil and flunarizine, blockers of VGCCs, is also well-established in migraine prophylaxis [101] . VGCCs may contribute to action potential generation, especially in the dendritic region of neurons. Low-threshold spikes, mediated by T-type calcium channels may trigger the activation of VGSCs and high-voltage activated calcium channels. Abnormalities of T channels have been demonstrated in childhood absence epilepsy. Disturbed functioning of thalamocortical neuronal circuits termed thalamocortical dysrhythmia [102] , which seems to underlie a variety of brain hyperexcitability disorders, involves T channel dysfunction. On the other hand high-voltage activated calcium channels are key players in triggering neurotransmitter release. Spinal cord hyperexcitability and nociception were found susceptible to a selective Ca V 2.3 antagonist [103] . Blockade of P/Q-type calcium channels inhibits cortical SD [104] , and a gain-of-function mutation of the corresponding gene (CACNA1A) is associated with a form of familial hemiplegic migraine, FHM-1, as well as some forms of episodic ataxia and spinocerebellar ataxia [105] . The anticonvulsive and antinociceptive drug, gabapentin, selectively binds to a non-channel forming calcium channel subunit ( 2 ) , and has been effective in migraine prevention [106] . This suggests that 2 is also a suitable anti-migraine drug target.
POTASSIUM CHANNELS
Various isoforms of potassium channels, namely the twopore-domain KCNK channel, ATP-sensitive channels, as well as inward rectifying channels are crucial in setting resting membrane potential, while other subtypes of potassium channels are responsible for repolarization following action potentials. Thus potassium channels represent major determinants of neuronal excitability [107] . Channelopathies associated with hypo-functioning of potassium channels can cause brain hyperexcitability disorders and opening of these channels results in decreased excitability. Thus, potassium channel openers may be useful for the treatment of hyperexcitability disorders, such as migraine [108] , while blockers of these channels can induce seizures. Most agents act on the channel pore itself, which is formed by subunits of a protein complex. The accessory subunit KV 1 accelerates the inactivation of this potassium channel type [109] . Thus, inhibition of the function of KV 1 can reduce neuronal hyperexcitability in diseases such as epilepsy, neuropathic pain, or migraine.
GLUTAMATE RECEPTORS
Agents inhibiting ionotropic glutamate receptors, including both NMDA and AMPA receptor antagonists, prevent cortical SD by decreasing neuronal excitation [110] [111] [112] . Furthermore, AMPA/kainate antagonist com-pounds, such as tezampanel, a tetrazolo-isoquinoline of Eli Lilly, is in clinical development as a preventive agent [113] . AMPA receptor antagonism is implicated in the therapeutic actions of topiramate, an antiepileptic agent, which has been commercialized for the prophylaxis of migraine headaches since 2004 [114] . Faria and Mody [115] found ifenprodil, an NR2B subunit selective NMDA antagonist to inhibit cortical SD in murine brain slices. Menniti et al. [116] found that CP-101,606 (a more selective NR2B antagonist) inhibited electrically evoked cortical SD in vivo, however the main focus of the authors was the neuroprotective aspect of this result. Recently, CP-101,606 and Ro-256981 were investigated by GSK [117] ; In their in vivo model both compounds inhibited cortical SD, strongly suggesting a possible therapeutic utility of NR2B antagonists in migraine.
Various animal pharmacology experiments have shown that glutamate is largely responsible for signal transmission in the neural circuit involved in migraine, and mGluR5 receptors are found at strategic points along these pathways. Addex Pharmaceutical has started Phase II investigation with its mGluR5 antagonist compound, ADX10059, in a doubleblind, controlled comparison with placebo, to treat moderate or severe migraine headache, in an outpatient setting and a successful end of Phase IIa was announced in 2007.
INHIBITORY NEUROTRANSMITTER RECEPTORS
Mutation of 1 subunits of glycine receptors results in hyperekplexia (exaggerated startle responses and seizures in infants), indicating an abnormally increased cortical excitability [118] . Furthermore, modulation of 3 glycine receptor function through the prostaglandin receptor EP2 possibly plays a key role in central sensitization associated with chronic pain [119] . Expression of glycine receptors in trigeminal neurons have been demonstrated [120, 121] , thus it might be interesting to test glycine receptor positive modulators in migraine models.
Another inhibitory receptor, the GABA receptor is somewhat less popular as a potential target for developing anti-migraine agents. Nevertheless, the GABA receptor modulatory effect of valproate may play a role in its ability to prevent migraine attacks. Drugs applied in the preventive therapy of migraine, among others valproate, inhibit experimental SD when applied chronically, in vivo [11] . Ganaxolone, a steroid compound in investigational phase, which acts independently from estrogen receptors, but potentiates GABA A receptors mediated inhibition, may have a role in hyperexcitability disorders. Propofol, a drug used in migraine therapy, and is able to abolish ongoing migraine in patients when applied intravenously at subanesthetic doses, also acts by enhancing the function of GABA A and glycine receptors.
FURTHER TARGETS
Female sex steroids seem to modulate cortical neuronal excitability. It has been shown recently that the threshold for cortical SD in transgenic mice containing one of the CACNA1A mutations observed in FHM patients appeared to be lower in female mice than in their male counterparts, which also had a reduced threshold compared to the wild-type mice. In addition, the prevalence of FHM is 2.5 times higher in women than in men [122] .
Anandamide, the endogenous ligand for the cannabinoid CB1 and CB2 receptors, is shown to be able to attenuate neurogenic dural vasodilation, as well as CGRP-and NOinduced dural vessel dilatation [123] . Therefore, the biology of anandamide receptors and their capacity to influence the action of trigeminovascular system might provide a further target that has no vasoconstrictor penalty.
Bradykinin may have a regulatory role on blood vessel functions as increased carotid blood flow and jugular NO level is found following common carotid artery administration of the peptide [124] . It would be important to investigate the potential implications of bradykinin receptors and their antagonists in migraine-related cerebrovascular dilatation, hyperalgesia and neurogenic inflammation.
Preclinical experiments have demonstrated that the TRPV1 receptors are expressed both centrally and peripherally in the trigeminal system and inhibition of TRPV1 with SB-705498, a novel, first in class TRPV1 receptor antagonist can both prevent and reverse established central sensitization [125] . Although a clinical Phase II study with SB-705498 for the treatment of migraine pain was terminated in 2007, GRC-6211 of Glenmark Pharmaceuticals is still in active development.
Several other membrane proteins have been identified as potential targets of anti-migraine drugs. The most important ones include G-protein coupled receptors involved in presynaptic regulation of neurotransmitter release, such as adenosine A1, H 3 , GABA B , D 2 , and neuropeptide Y receptors. Dopamine receptors are regarded as promising anti-migraine drug targets [126] . Neuropeptide Y is an important regulator of glutamatergic functions by inhibiting glutamate release tonically, thus, agonists of NPY receptors may be effective in several hyperexcitability disorders [127] . Biogenic amine and muscarinic receptors are key regulators of VGSCs and VGCCs through activation of G-proteins and protein kinases [53, 54] . Among drugs affecting neurotransmitter transporters serotonin and noradrenaline uptake blockers, used as antidepressants, have been applied successfully in prevention of migraine attacks. Connexins, which form gap junctions between astrocytes in the cortex, have been implicated in seizure spread and cortical SD [128] , and tonabersat, a gap junction antagonist, is being investigated in human trials [129] . Botulinum toxins, acting via proteolytic cleavage of SNARE proteins, thus interfering with the machinery of transmitter release from nerve terminals (vesicle docking and fusion), are also tried in migraine patients [77] .
Orexin and leukotriene receptors seem to be also relevant to migraine treatment. Hyperpolarization-activated cyclic nucleotide-gated (HCN) channels, cooperating with T-type calcium channels are thought to be important in several pathological conditions characterized by thalamocortical dysrhythmia (see above). Since migraine is one of these conditions [130] , useful prophylactic agents might be found among HCN blockers. Other potential target protein in antimigraine research is the acid-sensing ion channel (ASIC) family. ASIC is a voltage-independent, proton-activated receptor belonging to the epithelial sodium channels. It is implicated in pain perception and also in ischemic stroke, suggesting a potential role also in the development of migraine attack [131, 132] .
EXPERIMENTAL MODELS FOR IDENTIFICATION OF ANTI-MIGRAINE AGENTS
Selection of proper experimental models is critical in identifying new drug candidates. Here, we overview the most frequently used models used in anti-migraine drug research and development.
First-generation models mainly focused on events within pain-generating intracranial tissues, as well as their downstream consequences within brain. The early concept in migraine model development was that cerebral vasodilation is the crucial mechanism responsible for the onset of migraine. Several models were developed that can be used to test the vascular effects of anti-migraine drug candidates.
For in vitro studies on blood vessels, vascular segments are usually mounted in organ baths and contraction or relaxation is measured isometrically [133] . Data with isolated blood vessels have proved to be of high value, particularly in characterizing the pharmacological profile and coronary side-effect potential of vasoactive anti-migraine drugs.
in vivo Vascular models have been developed to mimic the carotid (extracranial) vasodilation that is likely to take place during a migraine attack [27] . Drug-induced constriction of carotid arteriovenous anastomoses in anaesthetized pigs is measured most frequently by using radioactive microspheres administered to the circulation [134] . Trigeminovascular activation can be directly studied using intravital microscopy through a closed cranial window in rats and mice [135] .
Electrical stimulation of the trigeminal ganglion can mimic symptoms of migraine in rats. The ganglion is stimulated repetitively, for several minutes [136, 137] , and facial skin or meningeal blood flow is measured by laser Doppler flowmetry [138] . Both vascular events and neuronal changes play a role in this model. Plasma protein extravasation is produced by antidromic stimulation of trigeminal ganglia and sensory nerves in rats suggesting an involvement of this phenomenon in migraine pathogenesis. Clinically effective anti-migraine agents inhibit this sterile neurogenic inflammation, suggesting that inhibition of plasma protein extravasation could be predictive of anti-migraine therapeutic activity [139, 140] . This method was used for demonstrating the anti-migraine effect of the kainate receptor antagonist LY466195 [113] .
In mechanistic studies on the trigeminal nociceptive mechanisms sensitization of trigeminal afferents is sometimes induced by inflammatory agents like endotoxin lipopolysaccharide (LPS). A pharmacological model of migraine based on this central sensitization was recently described by Martino and Perkins [141] , in which ultrasound vocalization to tactile stimulation (air puffs) is recorded in sensitized rats.
Irritant substances, e.g. capsaicin [142] or carrageenan [143] injected through the atlanto-occipital membrane of anaesthetized rodents to the meninges induce c-fos protein immunoreactivity in the trigeminal nucleus caudalis, bilaterally. The NMDA receptor antagonist MK-801 reduced capsaicin-induced c-fos expression in this model [142] . MK-801 also showed an inhibitory effect on Fos expression evoked by stimulation of the superior sagittal sinus [144, 145] . Both models seem suitable to study drug effects on trigeminovascular activation, a key element in migraine pathogenesis.
Infusion of the NO donor glycerine trinitrate (GTN) has been shown to cause headache after a delay of hours, with symptoms resembling migraine [146] . GTN infusion leads to Fos protein expression in the trigeminocervical complex, indicating that NO donors, in addition to their direct vascular effects can activate the trigeminovascular system as well [147] . Models based on GTN injection seem to be valuable tools in the study of anti-migraine drug effects in animals [148] , as well as that of central sensory sensitization associated with other chronic pain syndromes. CGRP has a similar potential to provoke vasodilatation in animal studies, which was prevented by an antagonist, BIBN4096BS. The same antagonist was also effective when vasodilatation was induced by transcranial electrical stimulation [149] , and antagonized headache following CGRP injection in humans [150] .
Neuronal alterations upstream to the above neurovascular changes have also been studied thoroughly in drug research. Recently introduced models of cortical SD are suitable for identification of novel ways of migraine prophylaxis. CSD, a sensitive indicator of neuronal hyperexcitability, has been deeply implicated in the pathomechanism of migraine [48] . It underlies not only the aura phenomena, but is likely to be involved in triggering migraine headache itself as well. The phenomenon can be induced both in in vitro and in vivo preparations. Using isolated cortical brain slices [49] SD can be evoked easily by mechanical injury, repetitive electrical stimulation, local application of excitatory substances, or simply by elevating potassium concentration. Changes can be monitored electrophysiologically, as a moving wave of temporal electronegativity of the tissue field potential, or optically, by recording intrinsic optical signals from the slice [151] . Cortical SD can also be elicited in anesthetized animals by local application of chemicals (a drop of highconcentration K + , or excitatory substances) as well as mechanical (pin prick) or electrical stimuli to the surface of the exposed cortex. DC potential recording, sometimes combined with measurement of blood flow changes, by using the laser Doppler technique in the cortex, is regarded as a relevant way of testing anti-migraine agents [117] .
Several migraine models are based on peripheral-and central sensitization, which are of key importance in the development of migraine headache. Sensitization of central trigeminovascular neurons, detected electrophysiologically, was inhibited by intravenous naproxen [89, 152] . Behavioural changes in freely moving animals after sensitization of the trigemino-vascular system is also suitable for testing anti-migraine agents, although these changes are relatively less characterized. In an experiment with such a complex model mechanical or tactile allodynia, was measured applying von Frey hairs, or thermal hyperalgesia [153] . In a similar model, described by Martino and Perkins [141] , sensitization of rats to tactile stimulation is induced by central inflammation. Other behavioural alterations existing in migraine patients e.g. photophobia or phonophobia can be theoretically studied in animals using e.g. the place preference test. Systemically injected kainic-acid induced hyperalgesia can be considered as a model of peripheral sensitization. In this model, kainic acid is administered into the peritoneal cavity, and 24 hours later a peak can be measured in thermal hyperalgesia using the hot plate test [154] . A lowered threshold is maintained for a period of several days. NMDA injected intrathecally also evokes thermal hyperalgesia, which is considered as a model of central sensitization [155] .
Genetic models, i.e. mice expressing human mutant proteins relevant to migraine mutations are also available and help us to understand the pathophysiology of familial hemiplegic migraine, and possibly also that of more common migraine subtypes [76] . Mutations in the P/Q-type calcium channel, the neuronal voltage-gated Na V 1.1 sodium channel, or the Na + /K + pump can result in familial hemiplegic migraine [156, 157] . Although the complex genetic background is yet to be clarified, ion channel genes seem to be the most important. A knock-in mouse carrying the human pure FHM-1 R192Q mutation gene shows increases in cortical excitability and has reduced threshold with increased velocity for SD [158] .
NEWLY EMERGING STRUCTURES FROM THE AREA OF ANTI-MIGRAINE RESEARCH; REVIEW ON RECENT PATENTS
In this section, we review the most important compounds recently published in the patent literature, grouping them according to their mechanism of action. In most patents covering a specified circle of compounds a broad range of possible therapeutic application is claimed. Of the huge number of recent patents that may be related to migraine therapy we tried to select those which claim to act on the most important neuronal targets implicated in the pathomechanism of migraine.
Ion Channel Blockers
Several sodium and calcium channel antagonists have been used in the preventive therapy of migraine. Recently we published a detailed review on voltage gated sodium channel blockers [90] . A new development since that time is a patent announced by Vertex claiming VGSC blockers of indolylpiperazine structure (16) for the treatment of pain disorders, among others migraine [159] . The compounds of another Vertex patent (17) show dual activity; besides inhibiting voltage-gated sodium (Na V 1.7 to Na V 1.9) channels, they also block VGCCs (preferably N-type Ca V 2.2 channels) [160] .
A few companies show research interest in developing Ntype calcium channel blockers for the treatment of pain syndroms. Wyeth [161] [162] [163] [164] has patented four series of aryl or heteroaryl-substituted carboxamides with N-type calcium channel (Ca V 2.2) blocker activity as analgesic agents against chronic and neuropathic pain (18) (19) (20) (21) . Another patent published by Euroceltique claims cyclourea (22) , and benzenesulphonamide (23) derivatives, which have N-type (some of them also L-type) calcium channel blocking effect. They are thought useful in the therapeutic field of stroke, epilepsy, migraine, etc. [165, 166] .
Recently, Shionogi Co. and Euroceltique have patented oxime derivatives (24) as N-type VGCC blockers for the above mentioned therapeutic area [167] . Voltage-gated K V 7 (KCNQ) channel activators may be useful for the treatment of pain. Quinazoline derivatives (25) from Neurosearch with activity on human K V 7.2 and K V 7.3 channels were published in 2007 [168] . Pyrrolo-isoquinoline compounds (26) from PainCeptor are stated to inhibit the activity of multiple ion channels, among them acid-sensing ion channel 1 (ASIC1) and 3 (ASIC3). These compounds were active in the rat formalin test and a rat model of thermal hyperalgesia, they are claimed for the treatment of pain and inflammatory conditions as well [169] . Fig. (10) . Pyrrolo-isoquinoline compound patented by PainCeptor. 
Vanilloid Receptor Modulators
Among the new developments in the field of antimigraine channel blocking agents some interesting new patents have been published on TRPV1 (VR1) modulators. AmorePacific has divulged such compounds with antagonist properties on TRPV1 [170] for the treatment of several types of pain, including migraine. Merck Sharp & Dohme has patented 2,3-substituted fused pyrimidin-4(3H)-ones as analgesic agents with the same mechanism of action [171] . Janssen's biaryl-derived amide TRPV1 antagonists also target various types of pain (inflammatory, neuropathic, etc.). [172] . Researchers of Astra-Zeneca have reported new spiro(imidazolidine-indole)-triones (27, 28) as TRPV1 antagonists for the therapeutic field of pain, obesity and migraine [173, 174] . Finally, Pfizer has disclosed [175] a series of quinoline-(29a) or naphthalen-carboxamides (29b), or pyridil-methylcyclopropanecarboxamide (30) [176] with TRPV1-antagonist activity. Their potential for use is treating of pain and related disorders. 
Glutamate Receptor Antagonists
Glutamate is an important neurotransmitter in pain transmission. The GABA A receptor agonist and glutamate antagonist Topiramate is one of the most widely used drugs in the prophylactic migraine market. Furthermore, a few agents acting through the glutamatergic system are under active development, e.g. ADX-10059 with mGluR5 receptor modulator activity, and FP-0011 of Faust Pharmaceuticals, glutamate release inhibitor, etc. Fused heteroaryl tri-(31, 32) and tetracyclic (33) compounds with metabotropic glutamate receptor mGluR1 antagonist activity have been published by scientists of Schering [177] [178] [179] . Besides migraine they are considered to have potential for treating anxiety, and other psychiatric disorders. Pfizer has reported a series of benzimidazolyl (34) and azabenzimidazolyl (35) compounds as mGluR2 potentiators [180, 181] . These compounds are expected to be useful for treating migraine, schizophrenia and epilepsy. Later, Pfizer has patented further benzimidazolyl-methylpiperidine (36, 37) derivatives with similar mechanism and indications [182, 183] . Janssen and Addex have developed 1,4-disubstituted 3-cyano-pyridone derivatives as positive mGluR2 receptor modulators for use in treating anxiety, migraine, schizophrenia, depression and epilepsy [184] .
Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonists
The large number of new patents indicates that, development of CGRP antagonists for the treatment of migraine is a very promising new trend, many big companies seem to be seriously interested in this research field.
Boehringer has reported various structural families as CGRP antagonists e.g. phenyl-triazolyl-piperidenyl derivatives (38) [185] , benzodiazepinone-piperidines (39) [186, 187] , and tetrahydroquinazolinyl-piperidine derivatives or fused heteroaryl cyclic systems [188] . All are predicted to be useful for treating various forms of headache, but also other pain problems as well as type 2 diabetes. Interestingly, the CGRP receptor antagonists of BristolMyers Squibb [189] also contain the benzodiazepinonepiperidine moiety, which is coupled with a tricyclic benzazepinone (40) . In another series of their anti-migraine compounds a quinolin-piperidine was combined with the above tricyclic benzazepinone (41) [190] . The above mentioned benzodiazepinone-piperidine moiety (42) was a building block of a new Vertex patent [191] too. This moiety seems to be advantageous for the CGRP receptor antagonistic activity. Another patent from Vertex has reported indenyl-spirohydantoin derivatives (43) with the same mechanism of action [192] . The compounds of both patents are claimed to have utility as anti-migraine agents. Scientists of Merck are very active in the research of CGRP antagonists. They have published compound families with various structures: e.g. phenyl-benzodiazepine derivatives [193, 194] , and phenyl-pyridones [195] . A tricyclic spirohydantoin moiety dominates the compounds of two recent patents (44, 45) [196, 197] . Further anti-migraine compounds contain the same tricyclic spirolactam system combined with carboxamide or amine moieties (46) (47) (48) [198] [199] [200] . They are intended to be used in intervention of migraine, headache, and cluster headache. The compounds of [201] , with the same indications, have a bicyclic spirohydantoin building block. 
Further Approaches
Enzymes belonging to the NO synthase (NOS) family are important players in the pathophysiology of migraine. NO has been shown to evoke headache in migraine patients, and inhibition of NO synthases seems to be a useful way of interfering with the disease process. Some NOS inhibitors have been investigated in anti-migraine clinical trials. Kalypsis Inc. has divulged (dihydroquinolin-4-ylmethyl) furan-2-carboxamide (49) derivatives as NOS inhibitors for the treatment of disorders which are in connection of NO production [202] . Neuraxon has patented benzimidazolylacetamidine derivatives (50) with dual NOS inhibitory and -opioid agonist activity for the prevention of both acute and chronic pain, including migraine or neuro-pathic pain [203] .
Merck company has imparted a series of sulfonylated piperazines (51) as cannabinoid CB1 receptor antagonists or inverse agonists for the treatment of obesity, but migraine was also claimed as further application [204] .
Astellas Pharma has developed 5-HT 2B and 5-HT 7 receptor antagonists for the treatment of irritable bowel syndrome and migraine (52) [205] . Korea Research Institute of Chemical Technology has patented substituted-1H-quinazoline-2,4-dione derivatives (53) as 5-HT 6 receptor antagonists with potential utility in the treatment of several CNS disorders, among others migraine [206] . Xenoport has divulged a series of crystalline, serinederived prodrugs of propofol (54) which are claimed for the treatment of migraine, postoperative nausea and/or vomiting [207] .
Tetrahydroprotoberberine derivatives (55) were patented as modulators of dopamine D 1 and D 2 receptors and were claimed for treatment of attention deficit hyperactivity disorder and migraine [208] . 
CURRENT & FUTURE DEVELOPMENTS
Expiration of the patents on the first triptan compounds in the near future is predicted to substantially decrease the size of the global anti-migraine drug market. However, it seems to be generally agreed that novel anti-migraine agents with substantially improved properties could well be placed on this reshaped market, since several problems are associated with the use of the presently available therapies; these include poor efficacy in a substantial portion of patients, slow onset and short duration of action and nonideal side-effect profile. The current migraine market represents significant unmet medical need regarding drugs that offer fast relief and keep the attacks from recurring.
The next breakthrough in the "post-triptan" era of acute migraine treatment is expected to be the launch of telcagepant (MK-0974) of Merck, as the first CGRP receptor antagonist. There are also clinical investigations with drug candidates planned to use as a preventive therapy. There are drugs already in use as anti-epileptics among them, but these compounds have not been optimized for the therapy of migraine. In general, there is a considerable need for agents affecting those pathological changes within the brain that are specifically associated with the development of migraine. This need justifies research for improved migraine therapy based on novel molecular targets. Indeed, the great number of recently published patents indicates that drug companies are highly active in the anti-migraine field. The huge progress in our understanding of the pathology underlying the disease helps to identify novel, migraine-specific molecular targets. We believe that agents that target mechanisms responsible for migraine-associated neuronal hyperexcitability and over-activation have good chances to become successful anti-migraine agents. Hopefully, research efforts will finally bring respite from debilitating headache to all migraine patients. 
